Share: Share on Facebook Share on Twitter Share on LinkedIn I recommend visiting to read:%0A%0A {0} %0A%0A {1}

Cushman & Wakefield Further Strengthens it's UK Life Sciences Capabilities with Two Key Appointments

London, 31 January 2024 – Global real estate services firm Cushman & Wakefield has further strengthened the specialist advice it provides to clients in the UK Life Sciences sector with two key appointments.
The firm has appointed Chloe Garth, Partner, to lead Life Sciences Valuation & Advisory and provide valuation advice to investors, developers and lenders operating across the UK. Garth has considerable experience in the Life Sciences sector, and across the wider London & South East market, a region that includes the Golden Triangle, one of the world’s leading life sciences and biotechnology clusters, with its points at Oxford, Cambridge, and London. Garth joined Cushman & Wakefield from JLL last year.

Tom Nuttall, Head of UK Valuation & Advisory at Cushman & Wakefield, said: “We have a strong track record in the sector and valued more than 30 million sq ft of Life Sciences real estate across the UK last year. Chloe has the specialist knowledge and experience for this new position leading our advice to clients, supporting them in making informed decisions and continuing our growth in this expanding sector.”

Chloe Garth, UK Life Sciences Valuation & Advisory lead at Cushman & Wakefield, said: “Life Sciences is a maturing market in the UK and the construction of more purpose-built stock, both in established and emerging clusters, is starting to make a dent in the supply-demand imbalance. I look forward to leading Cushman & Wakefield’s valuation activity in this fascinating sector.”

Cushman & Wakefield has also appointed Rory MacGregor to lead its Capital Markets activity in the Life Sciences sector. MacGregor was previously a Partner within the firm’s UK Life Sciences advisory team and has been advising clients in the sector since 2019. In his new role, MacGregor will work across EMEA, with a strong focus on the UK, specifically the Golden Triangle, in which Cushman & Wakefield has advised on several notable investment transactions.

These include working on behalf of the London Borough of Sutton to secure Aviva and Socius as funding and development partners for a 1m-sq-ft commercial life sciences campus at the London Cancer Hub, as well as advising GSK on their R&D campus at Stevenage, where Cushman & Wakefield brought in UBS Asset Management and Reef Group to realise the vision for a new biotech ecosystem on the remaining 33 acres of land.

Rory MacGregor, UK Life Sciences Capital Markets lead, Cushman & Wakefield, added: “I’m incredibly excited to lead and build upon Cushman & Wakefield’s strong Life Sciences Capital Markets offering. As a team, we have already been at the forefront of the sector having worked on market leading transactions such as the land disposal at The London Cancer Hub in 2023, GSK’s R&D Headquarters in 2022, and The Oxford Science Park in 2021.”
About Cushman & Wakefield
Cushman & Wakefield (NYSE: CWK) is a leading global commercial real estate services firm for property owners and occupiers with approximately 52,000 employees in nearly 400 offices and 60 countries. In 2023, the firm reported revenue of $9.5 billion across its core services of property, facilities and project management, leasing, capital markets, and valuation and other services. It also receives numerous industry and business accolades for its award-winning culture and commitment to Diversity, Equity and Inclusion (DEI), sustainability and more. For additional information, visit


Richard Coleman, Head of Communications EMEA
Richard Coleman

Head of EMEA Communications • London

What's new

Mike Gorman
Cushman & Wakefield Continues Living Sector Expansion With Two Key UK Residential Capital Markets Hires

Cushman & Wakefield has announced two Residential Capital Markets hires in the UK as it continues to expand its Living sector team. 

Vikki McCrindle • 16/05/2024

25 Baker Street
Cushman & Wakefield Signs For New West End Office At Derwent London’s 25 Baker Street

Cushman & Wakefield has exchanged contracts on new office accommodation at 25 Baker Street, London, a brand new, Derwent London development. Baker Street will replace Portman Square as Cushman & Wakefield’s West End office from September 2025.

Richard Coleman • 08/05/2024

Gillian Bowman
Cushman & Wakefield’s UK Valuation & Advisory Team Welcomes Partner and Head of Sustainability

Gillian Bowman joins from Knight Frank to take on the role.

Vikki McCrindle • 01/05/2024



Residential Market Commentary

There are early signs of optimism, with mortgage rates reducing, an uptick in mortgage approvals and completed sales, and annual house price growth moving into positive territory for the first time in over a year.
Millie Harper • 05/06/2024
vat in dilapidations
Article • Valuation

VAT in Dilapidations

VAT in respect of dilapidations is a complex subject with its own set of rules, regulations and case law. Opinions are usually divided, and much will depend on the circumstances.
Alex Charlesworth • 05/06/2024
Experiential Leisure banners webcard

Playgrounds of Tomorrow

A multitude of exciting experiential leisure venues that go beyond traditional food and drink offerings have taken centre stage within the city’s night life over recent years. Categorised as a blend of interactive games and exciting night-time venues, experiential leisure has become a key proponent of social lives in cities across the country, with the UK emerging as the premier market for prime competitive socialising operators. 
Dominic Bouvet • 03/06/2024

Edinburgh Hotel Market Spotlight

Edinburgh's hotel sector saw a 22% revenue increase and a nearly 69% rise in gross operating profit in Q1 2024, outpacing the UK average despite rising costs and increased hotel supply.
Lise Keller • 28/05/2024


Contact Our Team for a Personalized Consultation 
With your permission we and our partners would like to use cookies in order to access and record information and process personal data, such as unique identifiers and standard information sent by a device to ensure our website performs as expected, to develop and improve our products, and for advertising and insight purposes.

Alternatively click on More Options and select your preferences before providing or refusing consent. Some processing of your personal data may not require your consent, but you have a right to object to such processing.

You can change your preferences at any time by returning to this site or clicking on Cookies.
Agree and Close
These cookies ensure that our website performs as expected,for example website traffic load is balanced across our servers to prevent our website from crashing during particularly high usage.
These cookies allow our website to remember choices you make (such as your user name, language or the region you are in) and provide enhanced features. These cookies do not gather any information about you that could be used for advertising or remember where you have been on the internet.
These cookies allow us to work with our marketing partners to understand which ads or links you have clicked on before arriving on our website or to help us make our advertising more relevant to you.
Agree All
Reject All